Adelmidrol is an anti-inflammatory ethanolamide derivative of azelaic acid.
Contents
Description
Adelmidrol is the semisynthetic diethanolamide derivative of azelaic acid, and has a symmetrical chemical structure. It classed as an ALIAmide, and is similar to palmitoylethanolamide, the parent molecule in the ALIAmide class of drugs. ALIAmides are group of fatty acid derivatives with cannabimimetic properties, which have antiinflammatory and analgesic effects and are thought to act by reducing mast cell activation.
It is used extensively in Italy in veterinary medicine, to treat skin inflammation. In 2015 it was found the compound also exerts anti-inflammatory action given systemically in 10 mg per kg bodyweight.
Adelmidrol in pet animals and in atopic eczema
Adelmidrol has been shown to negatively control the behavior of canine skin MCs during pathophysiological conditions (i.e. healing of experimental wounds). In particular, a statistically significant increase of intracytoplasmatic granular content of dermal MCs was shown in adelmidrol (2%)-treated wounds compared to control, thus suggesting the compound is effectively able to down-modulate skin MC degranulation in dogs.
Chronic gingiva inflammation can be a difficult to treat medical problem in dogs. A similar anti-inflammatory effect was observed in these dogs, treated with a gel to reduce gingival inflammation. Twenty dogs were randomised to the adelmidrol gel and placebo. After 30 and 45 days, the dogs using the adelmidrol gel had significantly less inflammation of the gingiva.
Furthermore, the local application of adelmidrol has been recently confirmed to reduce MC responses during chronic experimental inflammation, as shown by the significant decrease of mediators selectively expressed by MCs and involved in skin inflammation, such as chymase.
Adelmidrol seems suitable for topical application, as it exhibits both hydrophilic and lipophilic features, which help it to be absorbed into the skin, as the epidermis is composed of alternating lipophilic and hydrophilic layers.
A 4-week topical treatment with adelmidrol 2% emulsion in children affected by mild atopic dermatitis resulted in complete resolution in 80% of cases, with no side effects and no relapses at 8-week follow up.